UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Systemic amyloidosis from A (AA) to T (ATTR): a review

Journal of internal medicine, 2021-03, Vol.289 (3), p.268-292

2021

Volltextzugriff (PDF)

Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients

Leukemia, 2014-05, Vol.28 (5), p.1122-1128

2014

Volltextzugriff (PDF)

Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma

Leukemia, 2017-12, Vol.31 (12), p.2791-2798

2017

Volltextzugriff (PDF)

Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents

Leukemia, 2016-11, Vol.30 (11), p.2208-2213

2016

Volltextzugriff (PDF)

Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis

Bone marrow transplantation (Basingstoke), 2013-04, Vol.48 (4), p.557-561

2013

Volltextzugriff (PDF)

Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category

Leukemia, 2017-07, Vol.31 (7), p.1562-1569

2017

Volltextzugriff (PDF)

Impact of cytogenetic classification on outcomes following early high-dose therapy in multiple myeloma

Leukemia, 2016-03, Vol.30 (3), p.633-639

2016

Volltextzugriff (PDF)

Quantification of circulating clonal plasma cells via multiparametric flow cytometry identifies patients with smoldering multiple myeloma at high risk of progression

Leukemia, 2017-01, Vol.31 (1), p.130-135

2017

Volltextzugriff (PDF)

Natural history of t(11;14) multiple myeloma

Leukemia, 2018-01, Vol.32 (1), p.131-138

2018

Volltextzugriff (PDF)

Revisiting conditioning dose in newly diagnosed light chain amyloidosis undergoing frontline autologous stem cell transplant: impact on response and survival

Bone marrow transplantation (Basingstoke), 2017-08, Vol.52 (8), p.1126-1132

2017

Volltextzugriff (PDF)

“Real-life” data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma—the Mayo Clinic experience

Blood cancer journal (New York), 2021-12, Vol.11 (12), p.196-196, Article 196

2021

Volltextzugriff (PDF)

Correction: Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial design

Leukemia, 2024-08, Vol.38 (8), p.1866-1866

2024

Volltextzugriff (PDF)

Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial design

Leukemia, 2021-12, Vol.35 (12), p.3604-3607

2021

Volltextzugriff (PDF)

Clinical presentation and outcomes in light chain amyloidosis patients with non-evaluable serum free light chains

Leukemia, 2018-03, Vol.32 (3), p.729-735

2018

Volltextzugriff (PDF)

Autologous stem cell transplant for multiple myeloma patients 70 years or older

Bone marrow transplantation (Basingstoke), 2016-11, Vol.51 (11), p.1449-1455

2016

Volltextzugriff (PDF)

Daratumumab, carfilzomib, and pomalidomide for the treatment of POEMS syndrome: The Mayo Clinic Experience

Blood cancer journal (New York), 2023-05, Vol.13 (1), p.91-91

2023

Volltextzugriff (PDF)

Second auto-SCT for treatment of relapsed multiple myeloma

Bone marrow transplantation (Basingstoke), 2013-04, Vol.48 (4), p.568-573

2013

Volltextzugriff (PDF)

Oncolytic measles viruses encoding interferon β and the thyroidal sodium iodide symporter gene for mesothelioma virotherapy

Cancer gene therapy, 2010-08, Vol.17 (8), p.550-558

2010

Volltextzugriff (PDF)

Outcomes of maintenance therapy with lenalidomide or bortezomib in multiple myeloma in the setting of early autologous stem cell transplantation

Leukemia, 2018-03, Vol.32 (3), p.712-718

2018

Volltextzugriff (PDF)

Pomalidomide–dexamethasone in refractory multiple myeloma: long-term follow-up of a multi-cohort phase II clinical trial

Leukemia, 2018-03, Vol.32 (3), p.719-728

2018

Volltextzugriff (PDF)

Prevalence and predictors of thyroid functional abnormalities in newly diagnosed AL amyloidosis

Journal of internal medicine, 2017-06, Vol.281 (6), p.611-619

2017

Volltextzugriff (PDF)

Pomalidomide (CC4047) plus low dose dexamethasone (Pom dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)

Leukemia, 2010-11, Vol.24 (11), p.1934-1939

2010

Volltextzugriff (PDF)

A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy

Leukemia, 2007-03, Vol.21 (3), p.529-534

2007

Volltextzugriff (PDF)

Predicting PBSC harvest failure using circulating CD34 levels: developing target-based cutoff points for early intervention

Bone marrow transplantation (Basingstoke), 2011-07, Vol.46 (7), p.943-949

2011

Volltextzugriff (PDF)

Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival

Leukemia, 2017-01, Vol.31 (1), p.92-99

2017

Volltextzugriff (PDF)

1 – 25 von 291

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(253)
Mit Volltextzugriff
(277)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Systemic amyloidosis from A (AA) to T (ATTR): a review

Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients

Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma

Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents

Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis

Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category

Impact of cytogenetic classification on outcomes following early high-dose therapy in multiple myeloma

Quantification of circulating clonal plasma cells via multiparametric flow cytometry identifies patients with smoldering multiple myeloma at high risk of progression

Natural history of t(11;14) multiple myeloma

Revisiting conditioning dose in newly diagnosed light chain amyloidosis undergoing frontline autologous stem cell transplant: impact on response and survival

“Real-life” data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma—the Mayo Clinic experience

Correction: Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial design

Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial design

Clinical presentation and outcomes in light chain amyloidosis patients with non-evaluable serum free light chains

Autologous stem cell transplant for multiple myeloma patients 70 years or older

Daratumumab, carfilzomib, and pomalidomide for the treatment of POEMS syndrome: The Mayo Clinic Experience

Second auto-SCT for treatment of relapsed multiple myeloma

Oncolytic measles viruses encoding interferon β and the thyroidal sodium iodide symporter gene for mesothelioma virotherapy

Outcomes of maintenance therapy with lenalidomide or bortezomib in multiple myeloma in the setting of early autologous stem cell transplantation

Pomalidomide–dexamethasone in refractory multiple myeloma: long-term follow-up of a multi-cohort phase II clinical trial

Prevalence and predictors of thyroid functional abnormalities in newly diagnosed AL amyloidosis

Pomalidomide (CC4047) plus low dose dexamethasone (Pom dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)

A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy

Predicting PBSC harvest failure using circulating CD34 levels: developing target-based cutoff points for early intervention

Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival

Suchergebnisse filtern